US Bancorp
URGN icon

US Bancorp’s UroGen Pharma URGN Stock Holding History

US Bancorp’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98K Buy
+81
New +$2.19K ﹤0.01% 3783
2026
Q1 		– Sell
-17
Closed -$398 – 4337
2025
Q4 		$398 Buy
+17
New +$369 ﹤0.01% 3939
2025
Q1 		– Sell
-47
Closed -$501 – 4367
2024
Q4 		$501 Hold
47
– – ﹤0.01% 4021
2024
Q3 		$597 Sell
47
-123
-72% -$1.83K ﹤0.01% 3938
2024
Q2 		$2.85K Buy
170
+36
+27% +$512 ﹤0.01% 3645
2024
Q1 		$2.01K Hold
134
– – ﹤0.01% 3725
2023
Q4 		$2.01K Buy
+134
New +$1.74K ﹤0.01% 3702
2022
Q1 		– Sell
-605
Closed -$6K – 4202
2021
Q4 		$6K Buy
605
+209
+53% +$2.95K ﹤0.01% 3605
2021
Q3 		$6K Buy
396
+215
+119% +$3.41K ﹤0.01% 3605
2021
Q2 		$3K Sell
181
-1,294
-88% -$23.4K ﹤0.01% 3765
2021
Q1 		$29K Sell
1,475
-435
-23% -$9.23K ﹤0.01% 2862
2020
Q4 		$35K Buy
1,910
+659
+53% +$13.8K ﹤0.01% 2666
2020
Q3 		$24K Buy
1,251
+918
+276% +$20.8K ﹤0.01% 2743
2020
Q2 		$9K Buy
333
+48
+17% +$1.17K ﹤0.01% 3139
2020
Q1 		$5K Buy
285
+138
+94% +$3.73K ﹤0.01% 3277
2019
Q4 		$5K Buy
147
+11
+8% +$300 ﹤0.01% 3291
2019
Q3 		$3K Hold
136
– – ﹤0.01% 3362
2019
Q2 		$5K Hold
136
– – ﹤0.01% 3295
2019
Q1 		$5K Hold
136
– – ﹤0.01% 3256
2018
Q4 		$6K Sell
136
-34
-20% -$1.53K ﹤0.01% 3175
2018
Q3 		$8K Buy
+170
New +$7.9K ﹤0.01% 3206

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

US Bancorp's URGN Position: Q2 2026 in Review

US Bancorp opened a new position in UroGen Pharma (URGN) in Q2 2026: 81 shares worth $2.98K. The stake represents ﹤0.01% of the portfolio and ranks #3783 among its holdings. This is a return to the name: US Bancorp previously reported a position in URGN as recently as Q4 2025.

US Bancorp first reported a position in URGN in Q3 2018 and has held it in 21 quarters since. The position peaked at $35K in Q4 2020. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • US Bancorp held 81 shares of UroGen Pharma worth $2.98K as of Q2 2026.
  • UroGen Pharma was a new US Bancorp position in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3783 holding.
  • US Bancorp first reported a position in UroGen Pharma in Q3 2018 and has held it in 21 quarters since.
  • US Bancorp's UroGen Pharma position peaked at $35K in Q4 2020.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.